Given the consensus that CD36 upregulation is one of the major MASLD drivers (Rada et al, 2020), it would be important to evaluate whether inhibiting TET1 can ameliorate MASLD. This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.